Teva Pharmaceuticals
TEVA
537 hedge funds and large institutions have $9.5B invested in Teva Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 172 increasing their positions, 218 reducing their positions, and 170 closing their positions.
5% less ownership
Funds ownership: 58.22% → 53.21% (-5%)
17% less funds holding
Funds holding: 650 → 537 (-113)
21% less repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 218
47% less call options, than puts
Call options by funds: $288M | Put options by funds: $548M
52% less capital invested
Capital invested by funds: $19.6B → $9.5B (-$10.1B)
59% less funds holding in top 10
Funds holding in top 10: 22 → 9 (-13)
61% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 170
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$487M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$246M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$150M |
| 4 |
NC
Northern Cross
Boston,
Massachusetts
|
+$112M |
| 5 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$94.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
-$568M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$377M |
| 3 |
Nordea Investment Management
Stockholm,
Sweden
|
-$286M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$175M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$146M |
TEVA Hedge Fund Activity: Q3 2017 in Review
537 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2017, worth a combined $9.5B — down 52% from $19.6B a quarter earlier.
Sellers outnumbered buyers: 170 funds closed out of TEVA and 66 opened new positions — a net loss of 104 holders — while 218 trimmed existing stakes and 172 added.
The largest buyer was Abrams Capital Management, opening a new position worth an estimated $487M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $568M.
- 537 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2017, down from 650 in Q2 2017.
- Funds reported $9.5B of Teva Pharmaceuticals stock for Q3 2017, down 52% quarter-over-quarter.
- 66 funds opened new Teva Pharmaceuticals positions in Q3 2017 and 170 closed out, a net change of -104 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2017 was Abrams Capital Management, an estimated $487M added.
- The largest Teva Pharmaceuticals seller in Q3 2017 was Barrow, Hanley, Mewhinney & Strauss, an estimated $568M sold.
Based on aggregated 13F filings for Q3 2017.